Skip to main content

Tepotinib + Ivonescimab

Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

  • RegistryNCT07619339
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMET Exon 14 Skipping Non-Small Cell Lung Cancer
  • SponsorMemorial Sloan Kettering Cancer Center
How Tepotinib + Ivonescimab worksNCT076193391 min

What the film says

Read the transcript

This trial is for adults with non-small cell lung cancer that has a MET exon 14 skipping change.

The idea: combine tepotinib, a daily pill that targets MET, with ivonescimab, an antibody given by vein every three weeks. The study tests up to two doses of tepotinib to find the best one with few or mild side effects.

This phase 1 study plans 16 patients. At Memorial Sloan Kettering Cancer Center in New York, Paul Paik leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07619339

    Adults; NSCLC with METex14 skipping; Tepotinib daily pill; ivonescimab IV every 3 weeks; Up to two doses; best dose with few or mild side effects; Phase 1; 16; MSK; Paul Paik

The drug

What is being tested.

Tepotinib will be administered at 225mg or 450mg oral daily continuously in every 3 week cycles.

Ivonescimab is administered IV Q3W on Day 1 of each cycle. The total duration of ivonescimab treatment is up to 24 months.

The study

How the trial runs.

The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Documentation of Disease
  • Patients must have pathologically confirmed non-small cell lung cancer. This includes, but is not limited, to histologies such as adenocarcinoma, squamous cell carcinoma, sarcomatoid carcinoma, and poorly differentiated carcinoma.
  • Patients must have documentation of MET exon 14 skipping present in their cancer using an FDA-approved assay done within a laboratory with CLIA, ISO/IEC, CAP, or similar certification.
  • Definition of Disease
  • Patients must have advanced or recurrent disease.
  • Advanced disease is defined as stage IV disease or stage IIIB/C disease not amenable to local therapy such as radiation or surgery.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.